Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1Breast 1

Conditions

Uveal Melanoma 2Melanoma 2Triple Negative Breast Neoplasms 1Neoplasm Metastasis 1Breast Neoplasms 1

Interventions

pembrolizumab 28Nivolumab 14Ipilimumab 7Cyclophosphamide 7spartalizumab 6atezolizumab 4Interleukin-2 4fludarabine 3durvalumab 3cemiplimab 3avelumab 3aldesleukin 3Specimen Handling 3Magnetic Resonance Spectroscopy 3Immune Checkpoint Inhibitors 3Docetaxel 3obinutuzumab 2epacadostat 2budigalimab 2bempegaldesleukin 2Pemetrexed 2Paclitaxel 2Leucovorin 2Carboplatin 2CTLA-4 Antigen 2Biopsy 2vocimagene amiretrorepvec 1venetoclax 1utomilumab 1toripalimab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Triple Negative Breast Neoplasms × CR011-vcMMAE × Dermatologic × Clear all
NCT03326258 2018-07-18

Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by Surgery

National Cancer Institute (NCI)

Phase 1/2 Withdrawn
BreastDermatologic

Uveal Melanoma, Breast Neoplasms, Melanoma, Neoplasm Metastasis, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡